HYTN Receives GMP Certificates for The United States, Bermuda and Israel
HYTN Innovations (OTC: HYTNF) has secured Good Manufacturing Practices (GMP) certificates from Health Canada for its Kelowna manufacturing facility, specifically for the United States, Bermuda, and Israel. The certificates, requested in February, validate HYTN's production processes and are important for drug registrations in these jurisdictions.
The company's Drug Establishment License (DEL) enables the fabrication, packaging, and labeling of non-sterile pharmaceuticals containing cannabis and psilocybin. HYTN currently operates in Canada, UK, Germany, and Australia, with these new certifications positioning them for expansion into additional markets.
HYTN Innovations (OTC: HYTNF) ha ottenuto i certificati di Buone Pratiche di Fabbricazione (GMP) da Health Canada per il suo stabilimento di produzione a Kelowna, specificamente per gli Stati Uniti, Bermuda e Israele. I certificati, richiesti a febbraio, convalidano i processi di produzione di HYTN e sono importanti per le registrazioni di farmaci in queste giurisdizioni.
La Licenza di Stabilimento Farmaceutico (DEL) dell'azienda consente la fabbricazione, confezionamento e etichettatura di prodotti farmaceutici non sterili contenenti cannabis e psilocibina. HYTN opera attualmente in Canada, Regno Unito, Germania e Australia, con queste nuove certificazioni che li posizionano per l'espansione in ulteriori mercati.
HYTN Innovations (OTC: HYTNF) ha asegurado los certificados de Buenas Prácticas de Manufactura (GMP) de Health Canada para su instalación de fabricación en Kelowna, específicamente para los Estados Unidos, Bermudas e Israel. Los certificados, solicitados en febrero, validan los procesos de producción de HYTN y son importantes para el registro de medicamentos en estas jurisdicciones.
La Licencia de Establecimiento Farmacéutico (DEL) de la empresa permite la fabricación, envasado y etiquetado de productos farmacéuticos no estériles que contienen cannabis y psilocibina. Actualmente, HYTN opera en Canadá, Reino Unido, Alemania y Australia, y estas nuevas certificaciones los posicionan para expandirse a nuevos mercados.
HYTN Innovations (OTC: HYTNF)는 켈로나 제조 시설에 대해 캐나다 보건부로부터 미국, 버뮤다 및 이스라엘을 위한 우수 제조 관리(GMP) 인증을 확보했습니다. 2월에 요청된 이 인증서는 HYTN의 생산 프로세스를 검증하며, 이러한 관할권에서의 약물 등록에 중요합니다.
회사의 의약품 제조 라이센스(DEL)는 대마초와 실로시빈을 포함한 비멸균 의약품의 제조, 포장 및 라벨링을 허용합니다. HYTN은 현재 캐나다, 영국, 독일 및 호주에서 운영하고 있으며, 이러한 새로운 인증은 추가 시장으로의 확장을 위한 기반을 마련합니다.
HYTN Innovations (OTC: HYTNF) a obtenu des certificats de Bonnes Pratiques de Fabrication (GMP) de la part de Santé Canada pour son installation de fabrication à Kelowna, spécifiquement pour les États-Unis, les Bermudes et Israël. Les certificats, demandés en février, valident les processus de production de HYTN et sont importants pour les enregistrements de médicaments dans ces juridictions.
La Licence d'Établissement Pharmaceutique (DEL) de l'entreprise permet la fabrication, l'emballage et l'étiquetage de médicaments non stériles contenant du cannabis et de la psilocybine. HYTN opère actuellement au Canada, au Royaume-Uni, en Allemagne et en Australie, et ces nouvelles certifications les positionnent pour une expansion vers d'autres marchés.
HYTN Innovations (OTC: HYTNF) hat von Health Canada die Zertifikate für Gute Herstellungspraxis (GMP) für seine Produktionsstätte in Kelowna erhalten, und zwar speziell für die Vereinigten Staaten, Bermuda und Israel. Die im Februar beantragten Zertifikate validieren die Produktionsprozesse von HYTN und sind wichtig für die Arzneimittelregistrierung in diesen Jurisdiktionen.
Die Arzneimittelerlaubnis (DEL) des Unternehmens ermöglicht die Herstellung, Verpackung und Kennzeichnung von nicht sterilen Arzneimitteln, die Cannabis und Psilocybin enthalten. HYTN ist derzeit in Kanada, Großbritannien, Deutschland und Australien tätig, und diese neuen Zertifizierungen positionieren sie für eine Expansion in weitere Märkte.
- Obtained GMP certificates for three new strategic markets (US, Bermuda, Israel)
- Licensed to manufacture both cannabis and psilocybin pharmaceuticals
- Already established presence in multiple international markets (Canada, UK, Germany, Australia)
- None.
VANCOUVER, British Columbia, April 02, 2025 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a leader in pharmaceutical-grade cannabis manufacturing, is pleased to announce that it has received digital Good Manufacturing Practices (GMP) certificates (the “Certificates”) from Health Canada, confirming the GMP compliance of its Kelowna-based manufacturing facility. Issued under HYTN’s Drug Establishment Licence (“DEL”), these Certificates specifically acknowledge the Company’s GMP status for the United States, Bermuda, and Israel.
The Certificates, requested by HYTN in February, are important for drug registrations in jurisdictions where they apply. They also provide assurance in regions with limited regulatory frameworks, validating that HYTN’s production processes meet GMP standards. Notably, the Company’s DEL enables it to fabricate, package, and label non-sterile pharmaceuticals containing cannabis and psilocybin, positioning HYTN at the forefront of international markets looking to expand their pharmaceutical offerings.
“By demonstrating GMP compliance in markets that require it, HYTN is well-positioned to support new drug registrations, facilitate clinical trials, and offer contract manufacturing for both cannabis and psilocybin-based pharmaceuticals,” said Jason Broome, COO of HYTN. “Our continued commitment to GMP manufacturing strengthens our ability to evaluate global opportunities while driving value for partners and stakeholders alike.”
While HYTN is already active in commercial projects across Canada, the UK, Germany and Australia, the Company is also exploring expansions into additional markets. Securing GMP Certificates for the U.S., Bermuda, and Israel underscores HYTN’s progress in advancing GMP drug development and reaffirms its leadership in high-quality, compliant manufacturing practices to fuel international growth.
About HYTN Innovations Inc.
HYTN Innovations Inc. is a pharmaceutical company specializing in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybe-derived tryptamines. HYTN is dedicated to becoming a premier provider of these products across all federally regulated markets. The Company accomplishes this by strategically identifying market opportunities and effectively bringing innovative products to market through its advanced development platform.
About Good Manufacturing Practices (GMP)
GMP guidelines provide guidance for manufacturing, testing, and quality assurance to ensure that a manufactured product is safe for human consumption or use. Many countries have legislated that manufacturers follow GMP procedures and create their own GMP guidelines that correspond with their legislation.
For more information contact:
Elliot McKerr
Chief Executive Officer
1.866.590.9289
HYTN Investor Relations:
1.866.590.9289
investments@hytn.life
Forward-Looking Statements Disclaimer
The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents of this press release.
Certain information contained herein may constitute forward-looking information involving risks and uncertainties. Readers are cautioned not to place undue reliance on forward-looking statements, including, but not limited to, statements regarding the Company's GMP certification and its potential to facilitate drug registrations, global expansions, clinical trials, and contract manufacturing opportunities. Factors that could cause actual results to differ materially from forward-looking statements or that may affect the operations, performance, development, and results of the Company's business include, among other things: challenges or delays in international regulatory approvals; inability to maintain or comply with GMP standards; failure to secure or maintain necessary partnerships and relationships; inability to successfully expand into new jurisdictions; competitive pressures and market acceptance of the Company's products and services; regulatory changes impacting operations; and general economic and business conditions. Any statements that are not statements of historical fact are deemed forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release, and except to the extent required by applicable law, the Company assumes no obligation to update or revise forward-looking statements herein or otherwise, whether due to new information, future events, or otherwise. The forward-looking statements contained in this press release are expressly qualified by this cautionary note.
